IP Library › Granted Patent US 11,685,007
Granted Patent B2
US 11,685,007 · App. 16/949,567 · Granted Jun 27, 2023

Devices, systems, and methods for treatment of intracranial aneurysms

Inventors: Junwei Li (Irvine, CA); John Wainwright (Foothill Ranch, CA); Gaurav Girdhar (Ladera Ranch, CA); Stephen Sosnowski (Sherrills Ford, NC)
Assignee: COVIDIEN LP
B23P19/047A61B17/1214A61B17/12031A61B17/12113A61B17/12145A61B17/12172A61B17/12186A61B17/12168A61B2017/00526A61B2017/00557A61B2017/00862A61B2017/00929A61B2017/12054A61B2017/12063A61B2090/376A61B2090/3966
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,685,007
App. No.
16/949,567
Granted
Jun 27, 2023
Kind
B2
Abstract

Systems and methods for treating an aneurysm in accordance with embodiments of the present technology include intravascularly delivering an occlusive member to an aneurysm cavity and deforming a shape of the occlusive member via introduction of an embolic element to a space between the occlusive member and an inner surface of the aneurysm wall.

Claims (29)

1. A method for treating an aneurysm, the method comprising:

positioning a distal end of an elongated shaft in an aneurysm cavity;

releasing an occlusive member from the elongated shaft while the distal end of the elongated shaft is positioned within the aneurysm cavity such that the occlusive

member self-expands to assume a first expanded state in which the occlusive member forms a first shape, wherein, in the first expanded state, the occlusive member encloses an interior region having a first interior volume; and

delivering an embolic element between the occlusive member and the aneurysm wall to transform the occlusive member into a second expanded state in which the occlusive member encloses a second interior volume less than the first interior volume, wherein the occlusive member forms a second shape in the second expanded state that is different than the first shape in the first expanded state; and

wherein transforming the occlusive member into the second expanded shape includes injecting the embolic element to invert a portion of a sidewall of the occlusive member such that the portion is convex towards the aneurysm wall in the first expanded state and concave towards the aneurysm wall in the second expanded state.

2. The method of claim 1 , wherein transforming the occlusive member into the second expanded shape includes injecting the embolic element to urge a portion of a sidewall of the occlusive member in a direction away from the aneurysm wall and towards the interior region of the occlusive member.

3. The method of claim 1 , wherein transforming the occlusive member into the second expanded shape includes injecting the embolic element to invert a portion of a sidewall of the occlusive member such that the portion is convex towards the aneurysm wall in the first expanded state and concave towards the aneurysm wall in the second expanded state.

4. The method of claim 1 , wherein the embolic element comprises a liquid embolic.

5. The method of claim 1 , wherein delivering the embolic element occurs after the occlusive member is in the first expanded state.

6. The method of claim 1 , wherein the occlusive member has a globular or generally spherical shape in the first expanded state and a cup or bowl-shape in the second expanded state.

7. The method of claim 1 , wherein the embolic element comprises a biopolymer and a chemical crosslinking agent.

8. The method of claim 7 , wherein

the biopolymer includes chitosan, a derivative of chitosan, an analog of chitosan, or a combination thereof; and

the chemical crosslinking agent includes genipin, a derivative of genipin, an analog of genipin, or a combination thereof;

wherein the embolic element further comprises a physical crosslinking agent includes β glycerophosphate, a derivative of β glycerophosphate, an analog of β glycerophosphate, or a combination thereof.

9. The method of claim 8 , wherein the embolic element comprises a contrast agent.

10. The method of claim 1 , wherein the occlusive member is a braid.

11. The method of claim 1 , wherein the embolic element comprises a coil.

12. A method for treating an aneurysm, the method comprising:

positioning an expandable occlusive member in an initial expanded state within an aneurysm, wherein in the initial expanded state the occlusive member provides a number of layers across a neck of the aneurysm; and

doubling the number of layers of the occlusive member across the neck of the aneurysm by introducing an embolic element to an aneurysm cavity.

13. The method of claim 12 , wherein the number of layers after doubling is two.

14. The method of claim 12 , wherein the number of layers after doubling is four.

15. The method of claim 12 , wherein the occlusive member has a first shape in the initial expanded state, and wherein introducing the embolic element transforms the occlusive member from the initial expanded state to a secondary expanded state in which the occlusive member forms a second shape different than the first shape.

16. The method of claim 15 , wherein a volume enclosed by the first shape is greater than a volume enclosed by the second shape.

17. The method of claim 15 , wherein transforming the occlusive member into the second expanded shape includes injecting the embolic element to urge a portion of a sidewall of the occlusive member in a direction away from the aneurysm wall and towards an interior region of the occlusive member.

18. The method of claim 12 , wherein the occlusive member is a braid.

19. The method of claim 12 , wherein the embolic element comprises a coil.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: LI, JUNWEI; WAINWRIGHT, JOHN; GIRDHAR, GAURAV; SOSNOWSKI, STEPHEN
To: COVIDIEN LP
Reel/Frame 055702/0533 →
Continuity (7)
Provisional Application 62930333 · Nov 4, 2019
Provisional Application 62930357 · Nov 4, 2019
Provisional Application 62930487 · Nov 4, 2019
Provisional Application 62930324 · Nov 4, 2019
Provisional Application 62930421 · Nov 4, 2019
Provisional Application 62930303 · Nov 4, 2019
Related Publication 20210128169A1 · May 6, 2021
Cited By (6)
US 12,193,675 US 12,251,110 US 12,256,936 US 12,295,582 US 12,364,708 US 12,569,252